CA2902512A1 - Normalized calibration of analyte concentration determinations - Google Patents
Normalized calibration of analyte concentration determinations Download PDFInfo
- Publication number
- CA2902512A1 CA2902512A1 CA2902512A CA2902512A CA2902512A1 CA 2902512 A1 CA2902512 A1 CA 2902512A1 CA 2902512 A CA2902512 A CA 2902512A CA 2902512 A CA2902512 A CA 2902512A CA 2902512 A1 CA2902512 A1 CA 2902512A1
- Authority
- CA
- Canada
- Prior art keywords
- analyte
- normalized
- determining
- responsive output
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012491 analyte Substances 0.000 title claims abstract description 503
- 239000000523 sample Substances 0.000 claims abstract description 286
- 238000005259 measurement Methods 0.000 claims abstract description 193
- 239000013074 reference sample Substances 0.000 claims abstract description 93
- 230000004044 response Effects 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims description 149
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 109
- 239000008103 glucose Substances 0.000 claims description 109
- 238000005534 hematocrit Methods 0.000 claims description 66
- 210000004369 blood Anatomy 0.000 claims description 51
- 239000008280 blood Substances 0.000 claims description 51
- 238000012360 testing method Methods 0.000 claims description 46
- 230000007613 environmental effect Effects 0.000 claims description 15
- 238000011088 calibration curve Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 102000001554 Hemoglobins Human genes 0.000 claims description 13
- 108010054147 Hemoglobins Proteins 0.000 claims description 13
- 238000004891 communication Methods 0.000 claims description 11
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 8
- 108091005995 glycated hemoglobin Proteins 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 abstract description 123
- 238000010606 normalization Methods 0.000 abstract description 49
- 230000003287 optical effect Effects 0.000 abstract description 40
- 230000000694 effects Effects 0.000 description 29
- 230000002829 reductive effect Effects 0.000 description 24
- 239000004020 conductor Substances 0.000 description 17
- 230000009467 reduction Effects 0.000 description 16
- 238000006722 reduction reaction Methods 0.000 description 16
- 238000012935 Averaging Methods 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 239000013060 biological fluid Substances 0.000 description 14
- 238000012417 linear regression Methods 0.000 description 11
- 238000006479 redox reaction Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000004082 amperometric method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 5
- 238000002848 electrochemical method Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000004832 voltammetry Methods 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000003869 coulometry Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000000840 electrochemical analysis Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000005206 flow analysis Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000027756 respiratory electron transport chain Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000004313 potentiometry Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3274—Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/723—Glycosylated haemoglobin
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Physiology (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782520P | 2013-03-14 | 2013-03-14 | |
| US61/782,520 | 2013-03-14 | ||
| PCT/US2014/021870 WO2014159077A1 (en) | 2013-03-14 | 2014-03-07 | Normalized calibration of analyte concentration determinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2902512A1 true CA2902512A1 (en) | 2014-10-02 |
Family
ID=50439487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2902512A Abandoned CA2902512A1 (en) | 2013-03-14 | 2014-03-07 | Normalized calibration of analyte concentration determinations |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9958410B2 (enExample) |
| EP (2) | EP3276355B1 (enExample) |
| JP (3) | JP6305508B2 (enExample) |
| CN (1) | CN105378484B (enExample) |
| CA (1) | CA2902512A1 (enExample) |
| ES (1) | ES2812806T3 (enExample) |
| HK (1) | HK1221771A1 (enExample) |
| IL (1) | IL240815A0 (enExample) |
| TW (2) | TWI688768B (enExample) |
| WO (1) | WO2014159077A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11333611B2 (en) * | 2014-12-24 | 2022-05-17 | Koninklijke Philips N.V. | Measurements and calibration utilizing colorimetric sensors |
| WO2016185352A1 (en) | 2015-05-15 | 2016-11-24 | Ascensia Diabetes Care Holdings Ag | Improved biosensor system analyte measurement |
| WO2017195838A1 (ja) * | 2016-05-13 | 2017-11-16 | 栄研化学株式会社 | 測定対象物質の比較対象物質に対する割合を求める方法、プログラム、記憶媒体及び装置 |
| CN109690304A (zh) | 2016-07-12 | 2019-04-26 | 安晟信医疗科技控股公司 | 通过使用来自两个电极的交替输出信号进行电化学分析的方法 |
| CN109923417B (zh) * | 2016-09-08 | 2021-06-08 | 希米斯保健股份有限公司 | 诊断系统和方法 |
| CA3045090A1 (en) | 2016-12-05 | 2018-06-14 | Ascensia Diabetes Care Holdings Ag | Risk factor monitoring |
| JP6829158B2 (ja) * | 2017-07-18 | 2021-02-10 | 株式会社東芝 | データ処理装置、データ処理方法、およびプログラム |
| EP4485096A3 (en) * | 2018-01-23 | 2025-01-22 | DexCom, Inc. | Systems, devices, and methods to compensate for temperature effects on sensors |
| CN120093299A (zh) * | 2021-10-12 | 2025-06-06 | 深圳硅基传感科技有限公司 | 分析物浓度的校准方法及分析物传感器 |
| CN120381237A (zh) * | 2024-01-27 | 2025-07-29 | 深圳硅基传感科技有限公司 | 用于分析物传感器的灵敏度衰减的校正方法、系统及介质 |
| TWI893839B (zh) * | 2024-06-07 | 2025-08-11 | 國立臺灣大學 | 糖化血色素百分比偵測方法以及使用該方法之電子裝置 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6153069A (en) | 1995-02-09 | 2000-11-28 | Tall Oak Ventures | Apparatus for amperometric Diagnostic analysis |
| US5620579A (en) | 1995-05-05 | 1997-04-15 | Bayer Corporation | Apparatus for reduction of bias in amperometric sensors |
| JP3394262B2 (ja) | 1997-02-06 | 2003-04-07 | セラセンス、インク． | 小体積インビトロ被検体センサー |
| TW591230B (en) * | 1997-10-14 | 2004-06-11 | Bayer Ag | Method for improving the accuracy of the semi-quantitative determination of analyte in fluid samples |
| US7723099B2 (en) * | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
| CN1938589B (zh) * | 2004-03-31 | 2011-12-28 | 拜尔健康护理有限责任公司 | 用于实现用于生物传感器的基于阈值的校正函数的方法和装置 |
| ES2717135T3 (es) | 2005-07-20 | 2019-06-19 | Ascensia Diabetes Care Holdings Ag | Método para señalar al usuario para que añada una muestra adicional a una tira de prueba, método para medir la temperatura de una muestra y métodos para determinar la concentración de un analito basados en amperometría controlada |
| KR20130100022A (ko) | 2005-09-30 | 2013-09-06 | 바이엘 헬스케어 엘엘씨 | 게이트형 전압 전류 측정 분석물 결정 방법 |
| CA2643163C (en) * | 2006-02-27 | 2020-01-28 | Bayer Healthcare Llc | Temperature-adjusted analyte determination for biosensor systems |
| CA2650880C (en) * | 2006-05-08 | 2015-11-24 | Bayer Healthcare Llc | Abnormal output detection system for a biosensor |
| JP4785611B2 (ja) * | 2006-05-11 | 2011-10-05 | アークレイ株式会社 | 血液試料中の特定成分の濃度測定方法および装置 |
| US20080248581A1 (en) * | 2007-04-06 | 2008-10-09 | Bayer Healthcare Llc | Method for performing correction of blood glucose assay bias using blood hemoglobin concentration |
| US8000918B2 (en) * | 2007-10-23 | 2011-08-16 | Edwards Lifesciences Corporation | Monitoring and compensating for temperature-related error in an electrochemical sensor |
| US7928343B2 (en) * | 2007-12-04 | 2011-04-19 | The Board Of Trustees Of The University Of Illinois | Microcantilever heater-thermometer with integrated temperature-compensated strain sensor |
| BRPI0820670A2 (pt) * | 2007-12-10 | 2015-06-16 | Bayer Healthcare Llc | Compensação baseada em inclinação |
| US8614466B2 (en) * | 2008-11-18 | 2013-12-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Semiconductor for measuring biological interactions |
| JP5738770B2 (ja) | 2008-12-08 | 2015-06-24 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ | 信号調整を持つバイオセンサシステム |
| WO2011001917A1 (ja) * | 2009-06-30 | 2011-01-06 | アークレイ株式会社 | 分析装置および分析方法 |
| JP5350960B2 (ja) * | 2009-09-30 | 2013-11-27 | アークレイ株式会社 | 赤血球含有試料における目的成分の測定方法 |
| EP2544598B1 (en) * | 2010-03-12 | 2020-05-06 | The Board of Trustees of the University of Illionis | Waterproof stretchable optoelectronics |
| MX368104B (es) * | 2010-03-22 | 2019-09-19 | Ascensia Diabetes Care Holdings Ag | Compensacion residual para un biosensor. |
| CA2798938C (en) * | 2010-06-07 | 2018-08-07 | Bayer Healthcare Llc | Slope-based compensation including secondary output signals |
| JP5395005B2 (ja) * | 2010-07-20 | 2014-01-22 | アークレイ株式会社 | 糖化タンパク質の測定方法 |
| WO2012037369A1 (en) * | 2010-09-15 | 2012-03-22 | Mbio Diagnostics, Inc. | System and method for detecting multiple molecules in one assay |
| TW201305548A (zh) * | 2010-10-11 | 2013-02-01 | Mbio Diagnostics Inc | 用於細胞分析之系統及方法 |
| US9775806B2 (en) * | 2011-09-21 | 2017-10-03 | Ascensia Diabetes Care Holdings Ag | Analysis compensation including segmented signals |
-
2014
- 2014-03-07 EP EP17191150.6A patent/EP3276355B1/en active Active
- 2014-03-07 HK HK16109989.6A patent/HK1221771A1/zh unknown
- 2014-03-07 CN CN201480024116.7A patent/CN105378484B/zh active Active
- 2014-03-07 US US14/774,617 patent/US9958410B2/en active Active
- 2014-03-07 WO PCT/US2014/021870 patent/WO2014159077A1/en not_active Ceased
- 2014-03-07 CA CA2902512A patent/CA2902512A1/en not_active Abandoned
- 2014-03-07 EP EP14715482.7A patent/EP2972396A1/en not_active Ceased
- 2014-03-07 JP JP2016500871A patent/JP6305508B2/ja active Active
- 2014-03-07 ES ES17191150T patent/ES2812806T3/es active Active
- 2014-03-13 TW TW107124973A patent/TWI688768B/zh not_active IP Right Cessation
- 2014-03-13 TW TW103108988A patent/TWI636252B/zh not_active IP Right Cessation
-
2015
- 2015-08-25 IL IL240815A patent/IL240815A0/en unknown
-
2018
- 2018-03-06 JP JP2018039524A patent/JP6539369B2/ja active Active
- 2018-03-19 US US15/925,428 patent/US20180209932A1/en not_active Abandoned
-
2019
- 2019-06-07 JP JP2019106913A patent/JP6698919B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2972396A1 (en) | 2016-01-20 |
| TW201443427A (zh) | 2014-11-16 |
| CN105378484A (zh) | 2016-03-02 |
| US20180209932A1 (en) | 2018-07-26 |
| US9958410B2 (en) | 2018-05-01 |
| JP6698919B2 (ja) | 2020-05-27 |
| EP3276355A1 (en) | 2018-01-31 |
| EP3276355B1 (en) | 2020-05-06 |
| TWI636252B (zh) | 2018-09-21 |
| HK1221771A1 (zh) | 2017-06-09 |
| TWI688768B (zh) | 2020-03-21 |
| JP2016516191A (ja) | 2016-06-02 |
| TW201840977A (zh) | 2018-11-16 |
| JP6539369B2 (ja) | 2019-07-03 |
| CN105378484B (zh) | 2017-06-09 |
| JP2019164166A (ja) | 2019-09-26 |
| IL240815A0 (en) | 2015-10-29 |
| WO2014159077A1 (en) | 2014-10-02 |
| JP6305508B2 (ja) | 2018-04-04 |
| US20160018355A1 (en) | 2016-01-21 |
| JP2018105887A (ja) | 2018-07-05 |
| ES2812806T3 (es) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10921278B2 (en) | Slope-based compensation including secondary output signals | |
| US9958410B2 (en) | Normalized calibration of analyte concentration determinations | |
| JP6002274B2 (ja) | 信号調整を持つバイオセンサシステム | |
| US11913898B2 (en) | System error compensation of analyte concentration determinations based on pseudo-reference concentration and signal-based anchor parameters | |
| JP2012511160A5 (enExample) | ||
| JP2016517517A5 (enExample) | ||
| US9933441B2 (en) | Progressive approximation of sample analyte concentration | |
| HK1181850B (en) | Slope-based compensation including secondary output signals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190103 |
|
| FZDE | Discontinued |
Effective date: 20220830 |
|
| FZDE | Discontinued |
Effective date: 20220830 |
|
| FZDE | Discontinued |
Effective date: 20220830 |